14158 Results (Page 557 of 567)
All Market Research Reports
France Cancer Induced Bone Disease Therapeutics Market
France Cancer Induced Bone Disease Therapeutics Market valued at $36 Mn in 2022, projected to reach $52 Mn by 2030 with a 4.8% CAGR. The key drivers of this industry include the increasing prevalence of different cancers, unmet medical needs of the population, and supportive government initiatives. The industry is primarily dominated by players such as Amgen, Novartis, Pfizer, Roche, Eli Lilly, Johnson, and Bayer, among others.
China Congestive Heart Failure Therapeutics Market Analysis
The China Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $0.828 Bn in 2022 to $1.455 Bn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The market in China is driven by a confluence of various factors including a rapidly aging population, urbanization-induced lifestyle changes that increase the incidence of cardiovascular risk factors, and ongoing efforts to develop healthcare infrastructure, all of which contribute to increased demand for therapeutics. The China Congestive Heart Failure Therapeutics Market is dominated by key players from various therapeutic segments, including AstraZeneca, Bayer, Novartis, Eli Lilly, Merck, Sanofi, Jiangsu Hengrui Medicine, Shanghai Fosun Pharmaceutical, Shenzhen Chipscreen Biosciences, Guangzhou Kangchao Pharmaceutical, among others.
France Digital Biomarkers Market Analysis
France Digital Biomarkers Market was valued at $79.75 Mn in 2023 and is predicted to grow at a CAGR of 21.3% from 2023 to 2030, to $308.15 Mn by 2030. The key drivers of this industry include advancements in technology, the growing prevalence of chronic diseases, and rising healthcare costs. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Egypt Cancer Induced Bone Diseases Therapeutics Market
Egypt Cancer Induced Bone Disease Therapeutics Market valued at $4 Mn in 2022, projected to reach $6 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancer, expanding treatment options, and improved diagnoses. The industry is primarily dominated by players such as EVA, AstraZeneca, Merck, Eli Lilly, Pharco, Johnson & Johnson, Amgen, and Novartis among others.
Egypt Congestive Heart Failure Therapeutics Market Analysis
The Egypt Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $29 Mn in 2022 to $51 Mn by 2030, with a CAGR of 7.3% during the forecast period of 2022-2030. The primary drivers in Egypt are the increasing incidence of cardiovascular illnesses, increased consciousness, early detection made possible by technological developments in the field, and the revolutionary stage of CHF treatments with ongoing research and development. The Egypt Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Roche, Gilead Sciences, Copad Pharma, EVA Pharma, Pharco, Pharmaceuticals, Tabia Pharmaceuticals, etc, among various others.
China Biosensors Market Analysis
The China Biosensors Market was valued at $2323.2 Mn in 2023 and is predicted to grow at a CAGR of 9.5% from 2023 to 2030, to $4385.1 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the China Biosensors Market are Abbott Laboratories, Biosensors International, Bio-Rad International, DowDuPont, and Masimo Corporation, among others.
Germany Digital Biomarkers Market Analysis
Germany Digital Biomarkers Market was valued at $106.14 Mn in 2023 and is predicted to grow at a CAGR of 20.5% from 2023 to 2030, to $391.55 Mn by 2030. The key drivers of this industry include advancements in technology, the growing prevalence of chronic diseases, and the focus on preventative care. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Saudi Arabia Medication Access Programs Market Analysis
The Saudi Arabia Medication Access Programs Market was valued at $93.3 Mn in 2023 and is predicted to grow at a CAGR of 16.1% from 2023 to 2030, to $265.3 Mn by 2030. The key drivers of this industry include increasing chronic disease burden, government initiatives, and pharmaceutical innovation. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
France Congestive Heart Failure Therapeutics Market Analysis
The France Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $283 Mn in 2022 to $412 Mn by 2030, with a CAGR of 4.8% during the forecast period of 2022-2030. The key drivers in France include the aging population, contributing to an increased demand for CHF treatments, ongoing advancements in pharmaceutical research leading to innovative therapies, and government initiatives and reimbursement policies supporting accessibility. The France Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, Servier, Amgen, Otsuka Pharmaceuticals, Lexicon Pharmaceuticals, Tenex Therapeutics, etc, among various others.
Egypt Biosensors Market Analysis
The Egypt Biosensors Market was valued at $80.9 Mn in 2023 and is predicted to grow at a CAGR of 9.5% from 2023 to 2030, to $152.7 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, aging population, and growing demand for Point-of-Care (POC) testing. The prominent players of the Egypt Biosensors Market are BM-Egypt, Kimal, Medtronic, Abbot Laboratories, and Johnson & Johnson, among others
China Digital Biomarkers Market Analysis
China Digital Biomarkers Market was valued at $233.12 Mn in 2023 and is predicted to grow at a CAGR of 23.8% from 2023 to 2030, to $1,039.03 Mn by 2030. The key drivers of this industry include the rising burden of chronic diseases, government initiatives, and a focus on personalized medicine. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
UAE Medication Access Programs Market Analysis
The UAE Medication Access Programs Market was valued at $27.4 Mn in 2023 and is predicted to grow at a CAGR of 15.6% from 2023 to 2030, to $75.7 Mn by 2030. The key drivers of this industry include increasing healthcare expenditure, government initiatives, and the rising prevalence of chronic disease. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
China Cancer Induced Bone Disease Therapeutics Market
China Cancer Induced Bone Disease Therapeutics Market valued at $105 Mn in 2022, projected to reach $184 Mn by 2030 with a 7.3% CAGR. The key drivers of this industry include the rising incidence of cancers, government initiatives, and untapped market potential. The industry is primarily dominated by players such as Siemen, Hengrui, Shanghai Pharma, Johnson & Johnson, Novartis, and Amgen among others.
Indonesia Congestive Heart Failure Therapeutics Market Analysis
The Indonesia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $62 Mn in 2022 to $97 Mn by 2030, with a CAGR of 5.8% during the forecast period of 2022-2030. The growth of the Indonesia Congestive Heart Failure Therapeutics Market is driven by the increasing prevalence of cardiovascular conditions among an aging population, government initiatives enhancing accessibility and affordability, and the potential for healthcare infrastructure improvements, particularly in rural areas. The Indonesia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, Sanofi, AstraZeneca, Bayer, Eli Lilly, Merck, Kalbe Pharma, Kimia Pharma, Pharos, Indopharma, etc., among various others.
France Biosensors Market Analysis
The France Biosensors Market was valued at $794.8 Mn in 2023 and is predicted to grow at a CAGR of 7.0% from 2023 to 2030, to $1276.2 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the France Biosensors Market are Villard Medical, Bio-Rad International, Masimo Corporation, Meridian Bioscience, and Biosensors International, among others.
Indonesia Digital Biomarkers Market Analysis
Indonesia Digital Biomarkers Market was valued at $17.40 Mn in 2023 and is predicted to grow at a CAGR of 22.3% from 2023 to 2030, to $71.21 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, government initiatives, and a growing focus on preventative care. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Brazil Medication Access Programs Market Analysis
The Brazil Medication Access Programs Market was valued at $137.2 Mn in 2023 and is predicted to grow at a CAGR of 15.6% from 2023 to 2030, to $378.6 Mn by 2030. The key drivers of this industry include the high prevalence of chronic disease, the large uninsured population, and government initiatives. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
Canada Cancer Induced Bone Diseases Therapeutics Market
Canada Cancer Induced Bone Disease Therapeutics Market valued at $104 Mn in 2022, projected to reach $163 Mn by 2030 with a 5.8% CAGR. The key drivers of this industry include rising cancer incidence, increased research and development, and advancements in cancer diagnostics. The industry is primarily dominated by players such as Amgen, Pfizer, Merck, Eli Lilly, Novartis, Bayer, and Johnson & Johnson, among others.
Japan Congestive Heart Failure Therapeutics Market Analysis
The Japan Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $640 Mn in 2022 to $1,044 Mn by 2030, with a CAGR of 6.3% during the forecast period of 2022-2030. The primary driving factors include the growing emphasis on quality of life, technological developments in medicine that provide novel therapeutic approaches, and the rising incidence of heart failure as a result of aging populations and sedentary lifestyles in Japan. The Japan Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Merck, Pfizer, Boehringer Ingelheim, Otsuka, Sumitomo Pharma, Eisai, Meiji Seika Pharma, etc, among various others.
Germany Biosensors Market Analysis
The Germany Biosensors Market was valued at $1057.7 Mn in 2023 and is predicted to grow at a CAGR of 6.2% from 2023 to 2030, to $1611.6 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the Germany Biosensors Market are Lifesensors, Siemens Healthcare, B. Braun Melsungen AG, Meridian Bioscience, and Biosensors International, among others.
Japan Digital Biomarkers Market Analysis
Japan Digital Biomarkers Market was valued at $180.26 Mn in 2023 and is predicted to grow at a CAGR of 22.8% from 2023 to 2030, to $759.08 Mn by 2030. The key drivers of this industry include the growing prevalence of chronic diseases, the aging population, and the focus on innovation. The industry is primarily dominated by ActiGraph LLC, AliveCor Inc., Koneksa, and Altoida Inc. among others.
Mexico Medication Access Programs Market Analysis
The Mexico Medication Access Programs Market was valued at $82.3 Mn in 2023 and is predicted to grow at a CAGR of 14.85% from 2023 to 2030, to $217 Mn by 2030. The key drivers of this industry include healthcare reforms, disease burden, and government support. The industry is primarily dominated by players such as Gilead Sciences, Takeda Pharmaceuticals, Pfizer, and Novartis among others.
Canada Car T-Cell Therapy Market
Canada Car T-Cell Therapy Market valued at $232 Mn in 2022, projected to reach $393 Mn by 2030 with a 6.8% CAGR. The growing occurrence and prevalence of cancer worldwide, driven by factors like population aging, unhealthy lifestyles, and environmental influences, contribute to an expanding pool of patients who may potentially benefit from CAR T-Cell therapy, thereby expanding the market for this treatment. The top pharmaceutical entities presently operating in the market are Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Celgene, Johnson & Johnson, Cellectis, Atara Biotherapeutics, Adaptimmune Therapeutics, Poseida Therapeutics and UCAR-T.
Malaysia Congestive Heart Failure Therapeutics Market Analysis
The Malaysia Congestive Heart Failure Therapeutics Market is anticipated to experience a growth from $17 Mn in 2022 to $26 Mn by 2030, with a CAGR of 6% during the forecast period of 2022-2030. The market in Malaysia is driven by the escalating incidence due to aging demographics and unhealthy lifestyle choices, supported by proactive government initiatives to enhance healthcare accessibility and affordability, along with the expanding coverage of CHF medications by insurance policies. Malaysia Congestive Heart Failure Therapeutics Market encompasses various key players across different therapeutic segments, including Novartis, AstraZeneca, Bayer, Abbott, Roche, Merck, DuoPharma, Pharmaniaga, Hovid, Apex Bio, etc., among various others.
India Biosensors Market Analysis
The India Biosensors Market was valued at $525.6 Mn in 2023 and is predicted to grow at a CAGR of 11% from 2023 to 2030, to $1091.2 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, increasing demand for accurate disease diagnosis, and growing demand for Point-of-Care (POC) testing. The prominent players of the India Biosensors Market are i- SENS, SD Biosensor, Fortune Biosolutions, Glowvista Instruments, and Healthium Medtech, among others.
